Health insurance company Cigna (NYSE: CI) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 10.4% year on year to $72.5 billion. On the other hand, the company’s full-year revenue guidance of $280 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $8.08 per share was 2.5% above analysts’ consensus estimates.

Is now the time to buy CI? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Cigna’s fourth quarter results were well received by the market, reflecting the company’s ability to navigate industry disruptions and deliver on key growth priorities. Management credited the quarter’s performance to robust expansion in its EverNorth specialty and care services, successful adoption of biosimilars, and operational discipline across its health benefits business. CEO David Cordani highlighted the company’s strategic investments, including the new pharmacy benefits model and expanded specialty offerings, noting, "We further expanded our specialty capabilities to serve hospitals and health systems, in part with our new investment in Shields Health Solutions." Cordani also emphasized Cigna’s focus on improving affordability and customer experience, particularly through initiatives like the Clarity solution and ongoing efforts to enhance digital engagement.

Looking ahead, Cigna’s forward guidance centers on the rollout of its rebate-free pharmacy benefits model, ongoing investments in digital tools, and further expansion in high-growth specialty segments. Management believes these strategic actions will support stable margins and earnings growth, even as the company adapts to new regulatory requirements and shifts in the healthcare landscape. CFO Ann Dennison stated, “We remain focused on driving greater affordability and value for the patients and clients we serve, continuing to execute with discipline against our financial targets.” The company is also prioritizing technology infrastructure upgrades and partnership-driven service enhancements, aiming to ensure continued differentiation and long-term value creation.

Key Insights from Management’s Remarks

Management attributed the positive quarter to specialty pharmacy momentum, biosimilar uptake, and a proactive approach to regulatory changes, while highlighting new digital platforms and portfolio streamlining.

• Specialty pharmacy momentum: The EverNorth specialty and care services business experienced 14% revenue growth, fueled by increased demand for complex therapies and successful integration of biosimilar drugs, which management identified as a major secular opportunity.
• New pharmacy benefits model: Cigna introduced a transformative rebate-free pharmacy benefits model designed to improve transparency and lower out-of-pocket costs, aligning with regulatory shifts and the recent FTC settlement. This model is expected to become the standard offering by 2028.
• Portfolio streamlining: The company completed the divestiture of its Medicare business and invested in Shields Health Solutions, reinforcing its focus on segments where it sees sustainable growth and higher returns.
• Digital engagement advances: Cigna expanded its suite of AI-powered digital tools, including provider-matching and cost-tracking features, which have increased digital registrations and reduced call volumes among employer clients.
• Strategic partnerships: New collaborations, such as with Progyny and Headspace, broadened Cigna’s offerings in fertility and mental health, supporting employer clients seeking more comprehensive benefit solutions.

Drivers of Future Performance

Cigna’s outlook is driven by the adoption of its new pharmacy model, investments in specialty platforms, and ongoing cost containment efforts in response to evolving healthcare regulations and consumer demands.

• Rebate-free PBM rollout: Management expects the transition to the new pharmacy benefits model to preserve margin structure while improving cost transparency and patient affordability; at least 50% of EverNorth clients are expected to migrate by 2028, with Cigna Healthcare fully adopting in 2027.
• Specialty and biosimilar growth: Continued expansion in specialty pharmacy, particularly with biosimilars for conditions such as inflammatory and autoimmune diseases, is expected to drive high single-digit to low double-digit income growth in this segment, according to President Brian Evanko.
• Cost trend management: The company anticipates elevated medical cost trends will persist, but expects pricing actions and product mix shifts, especially in stop-loss and individual exchange businesses, to help offset these pressures and support disciplined margin expectations.

Catalysts in Upcoming Quarters

In the coming quarters, our team will monitor (1) the pace and breadth of client adoption for Cigna’s new rebate-free pharmacy benefits model, (2) the impact of specialty pharmacy and biosimilar uptake on EverNorth’s earnings trajectory, and (3) the effectiveness of cost management initiatives in a persistently high-cost healthcare environment. The rollout and operationalization of digital tools and new strategic partnerships will also be important indicators of execution.

Cigna currently trades at $282.00, up from $271.71 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.